"Viome is rapidly scaling to become a global leader in the longevity space, to promote better health outcomes today and our future generations, with exceptional innovation," said Harish Consul, Founder & CEO, Ocgrow Ventures.
PureTech intends to use the proceeds from the Transaction to further the advancement and growth of the Company and will update its cash runway guidance in due course.
Syncona led the financing round alongside specialist investors including LifeSci Ventures, Emerson Collective, and global biopharmaceutical company Bristol Myers-Squibb.
Vensica Therapeutics a clinical stage biopharmaceutical company, announced that it has closed an investment round of $16 million. The investment round was led by Israel Biotech Fund ("IBF"), a venture fund investing in Israeli and Israeli-related biotechnology and pharmaceutical...
James Leech, VP of Strategy & Corporate Development at Palette Life Sciences, stated “This debt financing provides Palette Life Sciences with considerable flexibility as we continue to expand upon our revenue generation and geographic footprint, including the sale of our exciting organ spacing product, Barrigel. The team can focus 100% of its resources on critical commercial and operational activities across the business.”
This latest investment brings the total venture funding raised by Sequential Skin to US $2.15M in 2021.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
The round also included participation from Adjuvant Capital, KdT Ventures, Plexo Capital, Endeavor Capital, Ingressive Capital and others.
Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases
Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies.
Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline
Cytovia eligible for up to $400 million in licensing milestones for Greater China rights.vCoordinated US and China clinical development of GPC3-targeted therapies for hepatocellular carcinoma.
Investors include Mercia Asset Management and BGF. Funding to further advance Locate Bio’s regenerative medicine pipeline of orthobiologics
Funding to advance novel NK and T cell modulator IMT-009 for the treatment of solid tumor and hematological cancers with an anticipated IND filing in 1H 2022.